Pfizer has reported positive results from the Phase III JADE MONO-1 clinical trial of its investigational Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients with moderate to severe atopic dermatitis.

The 12-week study compared a 200mg and 100mg dose of abrocitinib with placebo in 387 patients aged 12 years and over.

JADE MONO-1 forms part of Pfizer’s JADE global development programme.

The trial’s primary endpoint was the proportion of patients experiencing a score of clear (zero) or almost clear (one) skin on the Investigator Global Assessment (IGA), and a two-point or higher improvement relative to baseline.

The co-primary endpoint was the proportion of participants achieving at least a 75% or greater change in Eczema Area and Severity Index (EASI) score from baseline.

Key secondary endpoints were a four-point or greater decrease in itch severity on the pruritus numerical rating scale (NRS) and the magnitude of reduction in Pfizer’s pruritus and symptoms assessment for atopic dermatitis (PSAAD) scale.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Abrocitinib met all co-primary and secondary endpoints and displayed significant improvements in IGA, EASI-75, NRS ≥4-Point and EASI-90 response rates compared to placebo.

Improvements were observed to be significantly greater with both doses.

The most frequent abrocitinib-related treatment-emergent adverse events were short-lasting nausea, headache and nasopharyngitis, while subjects treated with placebo experienced dermatitis more frequently.

Pfizer Global Product Development Inflammation & Immunology chief development officer Michael Corbo said: “There is a critical need for additional treatment options for patients living with moderate to severe atopic dermatitis.

“We are pleased by these findings, which together with the recently reported positive top-line results from our second Phase III trial, encourage us that, if approved, abrocitinib may provide the first oral, once-daily treatment option for these patients.”

The company expects to report new data from the JADE programme early next year.